Skip to content

Jazz Pharmaceuticals JAZZ Other current assets

Other current assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.6B-16.9%
Amgen logo
AmgenAMGN
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Biogen logo
BiogenBIIB
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Royalty Pharma logo
Royalty PharmaRPRX

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsCurrent.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's other current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's other current assets?
Jazz Pharmaceuticals (JAZZ) reported other current assets of $285.3M in Q1 2026.
How has Jazz Pharmaceuticals's other current assets changed year-over-year?
Jazz Pharmaceuticals's other current assets increased by 9.8% year-over-year, from $259.82M to $285.3M.
What is the long-term trend for Jazz Pharmaceuticals's other current assets?
Over 5 years (2020 to 2025), Jazz Pharmaceuticals's other current assets has grown at a 16.3% compound annual growth rate (CAGR), from $152.49M to $323.9M.